BeiGene

BGNE

0 Obserwujący

$184.71

+0.49%

$0.90

Obserwuj

5 Sierpień

Upcoming Earnings

Market Cap.

P/E

Overview Metrics Financials

BGNE Fair Price

$784.90

Undervalued by 2.7%

Aby wyświetlić sprawiedliwą cenę akcji, musisz być członkiem Bulios Black.

My Notes

Začít psát

Profile

BeiGene, Ltd. (BGNE) is a global biopharmaceutical company based in China, focusing on the development and commercial distribution of innovative medicines for the treatment of various types of cancer and other diseases. Their portfolio includes cell therapy-based drugs, monoclonal antibodies, and other biologic therapeutics targeting different types of cancer, including lung, blood, gastrointestinal, and reproductive system cancers. BeiGene focuses on providing innovative and effective medicines that help cancer patients achieve better outcomes and improve their quality of life. The company also invests in research and development of new drug products and therapies to continuously innovate its portfolio and offer patients the latest treatment options. BeiGene, Ltd. (BGNE) shares may be attractive to investors seeking investments in biopharmaceutical companies with an emphasis on innovation and cancer treatment.

Feed

There are no posts to show right now.